Pyrazoloacridines, a New Class of Anticancer Agents with Selectivity against Solid Tumors in Vitro

Cancer Research

Volumn 47, Issue 16, 1987, Pages 4299-4304

  Sebolt, Judith S ^a   Scavone, Sylvia V ^a   Pinter, Cheryl D ^a   Hamelehle, Katherine L ^a   Von Hoff, Daniel D ^b   Jackson, Robert C ^a  

^a PFIZER INC   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; AMSACRINE; ANTINEOPLASTIC AGENT; DACTINOMYCIN; DOXORUBICIN; PD 114245; UNCLASSIFIED DRUG;

ANIMAL CELL; BLOOD AND HEMOPOIETIC SYSTEM; BREAST; CANCER CHEMOTHERAPY; CELL CULTURE; CHO CELL; COLON; CYTOTOXICITY; DRUG COMPARISON; DRUG CYTOTOXICITY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTOXICATION; LARGE INTESTINE; LEUKEMIA L 1210; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THERAPY; TUMOR CELL LINE;

ACRIDINES; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE; DNA; HUMANS; NEOPLASMS; OXYGEN; PYRAZOLES; RNA; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR STEM CELL ASSAY;

EID: 0023218399     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Baguley, B. C., Denny, W. A., Atwell, G. J., and Cain, B. F. Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. J. Med. Chem., 24: 170-177, 1981.
2. Nelson, E. M., Tewey, K. M., and Liu, L. F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase 11 on DNA by 4'-(9-acridinylamino)methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. USA, 81: 1361-1365, 1984.
3. Showalter, H. D. H., Johnson, J. L., Werbel, L. M., Leopold, W. R., Jackson, R. C., and Elslager, E. F. 5-[(Aminoalkyl)amino]-substituted anthra(l, 9-cd]-pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. J. Med. Chem., 27: 253-255, 1984.
4. Leopold, W. R., Nelson, J. M., Plowman, J., and Jackson, R. C. Anthrapyr-azoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res., 45: 5532-5539, 1985.
5. Leopold, W. R., Fry, D. W., Nelson, J. M., and Plowman, J. In vivo activity and biochemical characterization of substituted [l]benzothiopyrano[4, 3, 2-cd] indazoles, a novel class of DNA-binding anticancer agents. Proc. Am. Assoc. Cancer Res., 26: 253, 1985.
6. Werbel, L. M., Elslager, E. F., Ortwine, D. F., Shillis, J. L., Showalter, H. D. H., Worth, D. F., and Plowman, J. 2-(Aminoalkyl)-5-amino-2H-[l]ben-zothiopyrano[4, 3, 2-al]indazoles, a new class of anticancer agents. Proc. Am. Assoc. Cancer Res., 26: 254, 1985.
7. Radzikowski, C., Ledochowski, Z., Ledochowski, A., Wrzolek, S., Hrabowska, M., and Konopa, J. The evaluation of antitumor properties of acridine derivatives on the basis of the results from some in vivo and in vitro tests. Arch. Immunol. Ther. Exp., 15: 126-128, 1967.
8. Radzikowski, C., Ledochowski, A., Hrabowska, M., Ledochowski, Z., Wrzolek, S., and Konopa, J. A search for antitumor compounds. VI. Biologic studies. Antitumor properties of 29 new acridine derivatives of groups XVII-XVIII. Arch. Immunol. Ther. Exp., 17: 99-110, 1969.
9. Kwasniewska-Rokicinska, C., and Winkler, A. L. The effect of l-nitro-9-aminoacridine on Yoshida sarcoma sensitive and resistant to alkylating agents. Arch. Immunol. Ther. Exp., 17: 376-379, 1969.
10. Gniazdowski, M., Filipski, J., and Chorazy, M. Nitracrine. In: F. Hahn (ed.), Antibiotics V/Part 2, pp. 275–297. Berlin: Springer-Verlag, 1979.
11. Wilson, W. R., Denny, W. A., Twigden, S. J., Baguley, B. C., and Probert, J. C. Selective toxicity of nitracrine to hypoxic mammalian cells. Br. J. Cancer, 49: 215-223, 1984.
12. Brown, J. M. The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys., 8: 675-682, 1982.
13. Capps, D., Kesten, S. R., Shillis, J., and Plowman, J. 2-Aminoalkyl-5-nitropyrazolo[3, 4, 5-kl]acridines, a new class of anticancer agents. Proc. Am. Assoc. Cancer Res., 27: 111, 1986.
14. Levy, J. A., Virolainen, M., and Defendi, V. Human lymphoblastoid lines from lymph node and spleen. Cancer (Phila.), 22: 517-524, 1968.
15. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
16. Finlay, G. J., Baguley, B. C., and Wilson, W. R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem., 139: 272-277, 1984.
17. Von Hoff, D. D., Clark, G. M., Stogdill, B. J., Sarosdy, M. F., O'Brien, M. T., Cooper, J. T., Mattox, D. E., Page, C. P., Cruz, A. B., and Sandbach, J. F. Prospective clinical trial of a human tumor cloning system. Cancer Res., 43: 1926-1931, 1983.
18. Jackson, R. C., Fry, D. W., Boritzki, T., Roberts, B. J., Hook, K. E., and Leopold, W. R. The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity. Adv. Enzyme Regul., 23: 193—215, 1985.
19. Corbett, T. H. A selective two-tumor soft agar assay for drug discovery. Proc. Am. Assoc. Cancer Res., 26: 332, 1985.
20. Finlay, G. J., and Baguiey, B. C. The use of human cancer cell lines as a primary screening system for antineoplastic compounds. Eur. J. Cancer Clin. Oncol., 20: 947-954, 1984.
21. Sebolt, J. S., Leopold, W. R., Hamelehle, K. L., Pinter, C. D., and Plowman, J. Solid tumor selectivity of the 2-aminoalkyl-5-nitropyrazolo[3, 4, 5-kl]acridines, a novel class of DNA-binding antitumor agents. Proc. Am. Assoc. Cancer Res., 27: 421, 1986.
22. Thomlinson, R. H., and Gray, L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Brit. J. Cancer, 9: 539-549, 1955.
23. Brown, J. M. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br. J. Radiol., 52: 650-655, 1979.
24. Tannock, I. F. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumor. Br. J. Cancer, 22: 258-264, 1966.
25. Brady, L. W., Phillips, T. L., and Wasserman, T. H. Radiation sensitizers and radiation protectors combined with radiation therapy in cancer management. In: K. H. Karcher, H. D. Kozelnik, and G. Reinharz (eds.), Progress in Radio-Oncology II, pp. 161–175. New York: Raven Press, 1982.
26. Scavone, S. V., Sebolt, J. S., Pinter, C. D., Havlick, M. J., and Leopold, W. R. Biological and biochemical properties of the 2-aminoalkyl-5-nitropyra-zolo[3, 4, 5-kl]acridines (pyrazoloacridines). Proc. Am. Assoc. Cancer Res., 27: 277, 1986.
27. Stratford, I. J., Walling, J. M., and Silver, A. R. J. The differential cytotoxicity of RSU 1069: survival studies indicating interaction with DNA as a possible mode of action. Br. J. Cancer, 53: 339-344, 1986.
28. Fry, D. W., Boritzki, T. J., Besserer, J. A., and Jackson, R. C. In vitro DNA strand scission and inhibition of nucleic acid syntheses in L1210 leukemia cells by a new class of DNA complexers, the anthra[ 1, 9-cd]pyrazol-6(2H)-ones (anthrapyrazoles). Biochem. Pharmacol., 34: 3499-3508, 1985.
29. Momparler, R. L., Karon, M., Siegel, S. E., and Avila, F. Effect of Adriamycin on DNA, RNA and protein synthesis in cell-free systems and intact cells. Cancer Res., 36: 2891-2895, 1976.
30. Frei, III, E. The clinical use of actinomycin. Cancer Chemother. Rep., 58: 49-53, 1974.
31. Yamada, K., Nakamura, T., Tsuruo, T., Kitahara, T., Maekawa, T., Usaka, Y., Kurita, S., Masaoka, T., Takaku, F., Hirota, Y., Amaki, I., Osamura, S., Ito, M., Nakano, N., Ogura, M., Inagaki, J., and Onozawa, K. A phase II study of aclacinomycin A in acute leukemia in adults. Cancer Treat Rev., 7: 177-182, 1980.